Paris, France

Hélène Goulaouic

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 10.5

ph-index = 1

Forward Citations = 33(Granted Patents)


Company Filing History:


Years Active: 2010-2012

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Hélène Goulaouic in Pharmaceutical Chemistry

Introduction

Hélène Goulaouic, an accomplished inventor based in Paris, France, has made significant contributions to the field of pharmaceutical chemistry. With a focus on novel compounds that target specific disorders, his work is essential in advancing medical treatments.

Latest Patents

Goulaouic holds a patent for "Fluorene derivatives, composition containing said derivatives and the use thereof." This innovative invention pertains to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene. The patent outlines the pharmaceutical compositions comprising these derivatives and describes methods for treating disorders associated with Hsp90 protein activity by administering these compounds.

Career Highlights

He is currently associated with Aventis Pharma S.A., a leading company in the pharmaceutical industry, where he continues to explore and develop new therapeutic agents. His career has been marked by a commitment to improving health outcomes through innovative solutions in drug development.

Collaborations

Throughout his career, Goulaouic has collaborated with esteemed colleagues such as Patrick Mailliet and Luc Bertin. These collaborations have not only enhanced his research but also contributed to the broader scientific community's understanding of complex pharmaceutical applications.

Conclusion

Hélène Goulaouic stands out as a notable inventor whose work is pivotal in the realm of pharmaceuticals. His innovative approach to drug development, particularly through the exploration of fluorene derivatives, exemplifies the critical nature of inventions in improving healthcare and treatment strategies. With his patent, he has paved the way for future advancements in treating disorders linked to the Hsp90 protein.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…